Genomic Health Inc (GHDX)-Product Pipeline Analysis, 2017 Update

Genomic Health Inc (GHDX)-Product Pipeline Analysis, 2017 Update


  • Products Id :- GDME16224PD
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Genomic Health Inc (Genomic Health) is a provider of genomic-based clinical laboratory services for the treatment of cancer. The company's commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, and Onco type DX prostate cancer test. It perform extensive research and development activities to optimize the treatment of urologic cancers including prostate, bladder, and kidney cancers, and additional treatment decisions in breast and colon cancers. Genomic Health develops these products using its Onco type DX platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in the US, Europe, and Asia through its subsidiaries and offices. Genomic Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company Genomic Health Inc

The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research & Development strategies

Develop market-entry and market expansion strategies

Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Genomic Health Inc Company Overview 5

Genomic Health Inc Company Snapshot 5

Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview 5

Genomic Health Inc-Pipeline Analysis Overview 8

Business Description 8

Genomic Health Inc-Key Facts 9

Genomic Health Inc-Major Products and Services 10

Genomic Health Inc Pipeline Products by Development Stage 11

Genomic Health Inc Pipeline Products Overview 13

Liquid Biopsy-Based Bladder Cancer Test 13

Liquid Biopsy-Based Bladder Cancer Test Product Overview 13

Negative Biopsy Test-Prostate Cancer 14

Negative Biopsy Test-Prostate Cancer Product Overview 14

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay 15

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay Product Overview 15

Oncotype Dx-Kidney Cancer 16

Oncotype Dx-Kidney Cancer Product Overview 16

Oncotype Dx Colon Cancer Assay-Oxaliplatin 17

Oncotype Dx Colon Cancer Assay-Oxaliplatin Product Overview 17

Oncotype SEQ-Breast Cancer Test 18

Oncotype SEQ-Breast Cancer Test Product Overview 18

Oncotype SEQ-Tissue Mutation Panel 19

Oncotype SEQ-Tissue Mutation Panel Product Overview 19

Oncotype TRACK 20

Oncotype TRACK Product Overview 20

Prognostic Test-Melanoma 21

Prognostic Test-Melanoma Product Overview 21

Prognostic Test-Non Small Cell Lung Cancer 22

Prognostic Test-Non Small Cell Lung Cancer Product Overview 22

Prognostic Test-Non-Metastatic Renal Cell Carcinoma 23

Prognostic Test-Non-Metastatic Renal Cell Carcinoma Product Overview 23

Genomic Health Inc-Key Competitors 24

Genomic Health Inc-Key Employees 25

Genomic Health Inc-Key Employee Biographies 26

Genomic Health Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Genomic Health Inc, Recent Developments 29

Mar 29, 2017: Oncotype DX Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients 29

Mar 20, 2017: Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score in Reducing Burden and Cost of Chemotherapy 29

Mar 17, 2017: Genomic Health Unveils a Wealth of Data for the Oncotype DX Breast Cancer Test, Reinforcing Its Value in Improving Patient Outcomes and Leading to More Cost-Effective Management 31

Feb 16, 2017: Four New Studies of Oncotype DX Genomic Prostate Score (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection 32

Feb 14, 2017: Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook 33

Dec 22, 2016: Genomic Health Announces Inclusion of Oncotype DX in the 8th Edition of American Joint Committee on Cancer Criteria for Breast Cancer Staging 35

Dec 12, 2016: New data demonstrate that Oncotype DX can help guide treatment decisions before breast cancer surgery enabling more personalized care, including avoidance of full mastectomy 36

Dec 09, 2016: Genomic Health Announces Results from Multiple Oncotype DX Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World 37

Nov 29, 2016: Genomic Health Announces Presentation of Multiple Oncotype DX Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine 38

Nov 01, 2016: Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results 40

Appendix 42

Methodology 42

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

Genomic Health Inc Pipeline Products by Equipment Type 6

Genomic Health Inc Pipeline Products by Development Stage 11

List of Tables

Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview 5

Genomic Health Inc Pipeline Products by Equipment Type 6

Genomic Health Inc Pipeline Products by Indication 7

Genomic Health Inc, Key Facts 9

Genomic Health Inc, Major Products and Services 10

Genomic Health Inc Number of Pipeline Products by Development Stage 11

Genomic Health Inc Pipeline Products Summary by Development Stage 12

Liquid Biopsy-Based Bladder Cancer Test-Product Status 13

Liquid Biopsy-Based Bladder Cancer Test-Product Description 13

Negative Biopsy Test-Prostate Cancer-Product Status 14

Negative Biopsy Test-Prostate Cancer-Product Description 14

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay-Product Status 15

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay-Product Description 15

Oncotype Dx-Kidney Cancer-Product Status 16

Oncotype Dx-Kidney Cancer-Product Description 16

Oncotype Dx Colon Cancer Assay-Oxaliplatin-Product Status 17

Oncotype Dx Colon Cancer Assay-Oxaliplatin-Product Description 17

Oncotype SEQ-Breast Cancer Test-Product Status 18

Oncotype SEQ-Breast Cancer Test-Product Description 18

Oncotype SEQ-Tissue Mutation Panel-Product Status 19

Oncotype SEQ-Tissue Mutation Panel-Product Description 19

Oncotype TRACK-Product Status 20

Oncotype TRACK-Product Description 20

Prognostic Test-Melanoma-Product Status 21

Prognostic Test-Melanoma-Product Description 21

Prognostic Test-Non Small Cell Lung Cancer-Product Status 22

Prognostic Test-Non Small Cell Lung Cancer-Product Description 22

Prognostic Test-Non-Metastatic Renal Cell Carcinoma-Product Status 23

Prognostic Test-Non-Metastatic Renal Cell Carcinoma-Product Description 23

Genomic Health Inc, Key Employees 25

Genomic Health Inc, Key Employee Biographies 26

Genomic Health Inc, Other Locations 28

Genomic Health Inc, Subsidiaries 28

Glossary 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Genomic Health Inc, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies

select a license
Single User License
USD 750 INR 53430
Site License
USD 1500 INR 106860
Corporate User License
USD 2250 INR 160290

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com